Keyword: Regeneron Pharmaceuticals
What we're hearing so far? Ethics promises, cost-cutting updates, pipeline expansions—plus skinny on how and where secret talks happen.
Amid a restructuring of its partnership with Sanofi for Praluent and Kevzara, Regeneron is planning to lay off 15 New York staffers.
Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.
After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.
Thanks to Novartis' MedCo buyout pact, PCSK9 competition is about to get more intense. But can it really make its heart prospect work?
Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.
Sanofi and Regeneron's new crowdsource challenge “Agents of Change” looks for solutions around bullying in atopic dermatitis.
A look at third-quarter numbers shows many top players are rolling right along—though some Big Pharmas weren't so lucky.
Despite Regeneron's rhetoric, analysts are pessimistic about growth prospects for its I-O drug Libtayo and new trial data didn't calm their fears.
Regeneron is sharpening Eylea's edge with prefilled syringes, a launch in diabetic retinopathy and tests of a higher dose to increase its durability.